2. Krag D, Weaver D, Ashikaga T et al. The Sentinel Node in Breast Cancer-A multicentre validation study. N Engl J Med. 1998; 339:941-6

BIBLIOGRAFIA

1. Veronesi U, Paganelli G, Viale G et al. Sentinel Lymphnode Biopsy and Axillary Dissection in Breast Cancer: Results in a Large Series. J Natl Cancer Inst 1999;

91:368-73

2. Krag D, Weaver D, Ashikaga T et al. The Sentinel Node in Breast Cancer-A multicentre validation study. N Engl J Med. 1998; 339:941-6

3. Barros ACSD, Mori LJ, Nishimura D et al. Surgical Anatomy of the Internal Thoracic Lymph Nodes in Fresh Human Cadavers: Basis for Sentinel Node Biopsy.

World Journal of Surgical Oncology 2016; 14:135

4. Halsted WS. The results of operations for the cure of the cancer of breast performed at the Johns Hopkins Hospital fron June 1889 to January 1894. Johns Hopkins Hospital Bull 1894; 4:497-555

5. Meyer KK, Beck WC.Mastectomy performed by Lorenz Heister in the eighteenth century.Surg Gynecol Obstet 1984;159:391-394

6. Thorek M. Surgery of the breast. Modern Surgica Technique, 2

edition.

Philadelphia, PA:LB Lippincott 1949

7. Moore C. On the influence of inadequate operations on the theory of cancer. R Med Chir Soc 1867;1:244-280

8. Banks WM. On the removal of mammary cancer with extirpation of axillary glands as necessary accompaniment. BMJ 1882;2:1138-1141

9. Patey DH, Dyson WH. Prognosis of carcinoma of the breast in relation to the type of operation performed. Br J Cancer 1948; 2:7

10. Veronesi U, Cascinelli N, Mariani L et al. Twenty-year follow-up of a randomized study comparing breat-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002;347:1227-1232

11. Fisher B. The surgical dilemma in the primary therapy of invasive breast cancer: a critical aprrisal. Curr Probl Surg 1970; October:3-53

12. Giuliano AE, Kirgan DM, Guenther JM et al. Lymphatic Mapping and Sentinel Lymphadenectomy for Breast Cancer. Ann Surg1994; 220:391-401

13. Schwartz GF, Giuliano AE, Veronesi U. Proceedings of the Consensun Conference on the Role of Sentinel Lymphnode Biopsy in Carcinoma of the Breast, April 19- 22, 2001, Philadelphia, Pennsylvania. Cancer 2002; Volume 94/ Number 10: 2542- 2551

14. Mansel RE, Fallowfield L, Kissin M et al. Randomized Multicenter Trial of Sentinel Node Biopsy versus Standard Axillary Treatment in Operable Breast Cancer: the ALMANAC Trial. J Natl Cancer Inst 2006; 98:599-609

15. Cady B, Stone MD, Schuler JG et al. The new era in breast cancer: invasion, size and nodal involvement dramatically decreasing as a result of mammographic screening. Arch Surg 1996;131:301-308

16. Veronesi U, Paganelli G, Viale G et al. A Randomized Comparison of Sentilel- Node Biopsy with Routine Axillary Dissection in Breast Cancer. N Eng J Med 2003; 349:546-53

17. Baxter N, McCready D, Chapman JA et al. Clinical Behaviour of untreated axillary nodes after local treatment for primary breast cancer. Ann Surg Oncol 1996; 3:235- 40

18. Zurrida S, Galimberti V, Orvieto E et al. Radioguided Sentinel Node Biopsy to avoid Axillary Dissection in Breast Cancer. Annals of Surgical Oncology 1999;

7(1):28-31.

19. Luini A, Gatti G, Ballardini B et al. Developement of axillary surgery in breast

cancer. Annals of Oncology 2005;16:259-262

20. Management of early cancer of the breast:report on an international multicentre trial supported by the Cancer Research Campaign. Br Med J 1976;1:1035-8

21. Veronesi U, Galimberti V, Zurrida S et al. Sentinel Lymph node biopsy as an indicator for axillary dissection in early breast cancer. European Journal of Cancer 2001;37:454-458

22. Fisher B, Redmond C, Fisher ER et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation.

N Engl J Med 1985;312:674-81

23. Harris JR, Lippman ME, Veronesi U et al. Breast cancer (2). N Eng J Med 1992;

327:390-8

24. Fisher B. Laboratory and clinical research in breast cancer-a personal adventure:

the David A. Karnofsky Memoraila Lecture. Cancer Res 1980; 40:3863-74

25. Fisher B, Wolmark N, Bauer M. et al The accuracy of Clinical Nodal Staging and of Limited Axillary Dissection as a Determinant of Histologic Nodal Status in Carcinoma of the Breast. Surg Gynecol Obstet 1981; 152:765-772

26. Kinne D. Controversies in primary Breast Cancer Management. Am J Surg 1993;

166:502-508

27. Fisher C, Boyle S, Burke M et al. Intraoperative assessment of nodal status in the selection of patients with breast cancer for axillary cleareance. Br J Surg 1993;

80:457-458

28. Kitchen P, McLennan R, Mursell A. Node-positive breast cancer: a comparison of clinical and pathological findings and assessment of axillary cleareance. Aust N Z J Surg 1980; 50:580-583

29. Davies G, Millis R, Hayward J. Assessment of axillary lymph node status. Ann Surg 1980; 192:148-151

30. Pigott J, Nichols R, Maddox W et al. Metastasis to the upper levels of the axillary nodes in carcinoma of the breast and its implications for nodal sampling procedures. Surg Gynecol Obstet 1984; 158:255-259

31. Kissin MW, Thompson EM, Price AB et al. The inadequacy of axillary sampling in breast cancer. Lancet 1982; 1:1210-1212

32. Sacre R. Clinical evaluation of axillary lymph nodes to surgical and pathological findings. Eur J Surg Oncol 1986; 12:169-173

33. Moffat F, Senofsky G, Davis K et al. Axillary node dissection for early breast cancer: some is good, but all is better. J Surg Oncol 1992; 51:8-13

34. Senofsky G, Moffat F, Davis K et al. Total axillary lymphadenectomy in the management of breast cancer. Arch Surg 1991; 126:1336-1342

35. Forrest A, Stewart H, Roberts M et al. Simple Mastectomy and axillary node sampling (pectoral node biopsy) in the management of primary breast cancer Ann Surg 1982;196:371-378

36. Steele R, Forrest A, Gibson T et al. The efficacy of lower axillary sampling in obtaining lymph node status in breast cancer: a controlled randomized trial. Br J Surg 1985; 72:368-369

37. Kjaergaard J, Blichert -Toft M, Andersen J et al. Probability of false negative nodal staging in conjunction with partial axillary dissection in breast cancer. Br J Surg 1985; 72:365-367

38. Graversen H, Blichert-Toft M, Andersen J et al. Breast cancer: risk of axillary recurrence in node negative patients following partial dissection of the axilla. Eur J Surg Oncol 1988; 14:407-412

39. Mathiesen O, Bonderup O, Panduro J. Axillary sampling and the risk of erroneous

staging of breast cancer: an analysis of 960 consecutive patients. Acta Oncologica 1990; 29:721-725

40. Smith J, Gamez-Araujo J, Gallager H et al. Carcinoma of the breast: analysis of total lymph node involvement versus level of metastasis. Cancer 1977;39:527-532 41. Wilking N, Rutqvist L, Carstensen J et al. Prognostic significance of axillary nodal

status in primary breast cancer in relation to the number of resected nodes. Acta Oncologica 1992; 31:29-35

42. Cabanas RM. An approach for the treatment of penile carcinoma. Cancer 1977;39:456-66.

43. Morton D, Wen D, Cochran A. Management of Early-Stage Melanoma by intraoperative lymphatic mapping and Selective Lymphadenectomy: an alternative to routine elective lymphadenectomy or 'watch and wait'. Surg Oncol Clin North Am 1992; 1:247-259

44. Alex JC, Krag DN. Gamma-probe guidel localization of lymph nodes. Surg Oncol 1993;2:137-43

45. Veronesi U, Rilke F, Luini A, et al. Distribution of axillary node metastases by level of invasion: an analysis of 539 cases. Cancer 1986; 59:682-687

46. Veronesi U, Luini A, Galimberti V, et al. Extent of metastatic axillary involvement in 1446 cases of breast cancer. Eur J Surg Oncol 1990; 16:127-133

47. Zurrida S, Morabito A, Galimberti V et al. Importance of the level of axillary involvement in relation to traditional variables in the prognosis of breast cancer. Int J Oncol 1999;15:475-80

48. Giuliano AE. Sentinel Lymphadenectomy in primary breast carcinoma: an alternative to routine axillary dissection. J Surg Oncol 1996; 62:75-7

49. Albertini JJ, Lyman GH, Cox C et al. Lymphatic mapping and sentinel node biopsy in the patient with breast cancer. JAMA 1996; 276:1818-22

50. Veronesi U, Paganelli G, Galimberti V al. Sentinel-node biopsy to avoid axillary dissection in breast cancer with clinically negative Lymph-nodes. Lancet 1997;349:1864-7

51. Flett M, Stanton PD, Cooke TG. Lymphatic mapping and sentinel node biopsy in breast cancer. Br J Surg 1998; 85:991-3

52. Auchincloss H. The nature of local recurrence following radical mastectomy.

Cancer 1958; 11:611-618

53. Patey D, Dyson WH. The prognosis of carcinoma of the breast in relation to the type of operation performed.Br J Cancer 1948;2:7-10

54. Fisher B, Redmond C, Poisson R et al. Eight-year results of a randomized clinical trial comparing total mastectomy and lumpectomy with or without irradiation in the tratment of breast cancer. N Eng J Med 1989; 320:822-828

55. Borgstein PJ, Pijpers R, Comans EF et al. Sentinel lymph node biopsy in breast cancer: guidelines and pitfalls of lymphoscintigraphy and gamma probe detection. J Am Coll Surg 1998; 186:257-283

56. Klimberg V, Rubio IT, Henry R et al. Subareolar versus peritumoural injection for location of the sentinel lymph node. Ann Surg 1999; 229:860-865

57. Pater J, Parulekar W. Sentinel Lymph Node Biopsy in Early Breast Cancer: has its time come? J Natl Cancer Inst 2006; 98:568-569

58. Veronesi U, Luini A, Galimberti V et al. Extent of metastatic axillary involvement in 1446 cases of breast cancer. Eur J Surg Oncol 1990;16:127

59. Cabanes PA, Salmon RJ, Vilcoq JR et al. Value of axillary dissection in addiction to

lumpectomy and radiotherapy in early breast cancer. Lancet 1992;339:1245-1248

60. Diab SG, Hilsenbeck SG, de Moore C et al. Radiation therapy and survival in

breast cancer patients with 10 or more positive axillary lymph nodes treated with mastectomy. J Clin Oncol 1998;16:1655-1660

61. Haffy G, Ward BA. Is breast conserving surgery with radiation superior to mastectomy in selected patients?Cancer J Sci Am 1997;3:2-3

62. Orr RK. The impact of prophylactic axillary node dissection on breast cancer survival-a Bayesian meta-analysis. Ann Surg Oncol 1999;6:17-18

63. Greco M, Agresti R, Cascinelli N et al. Breast cancer patients treated witout axillary surgery:clinical implications and biologic analysis. Ann Surg 2000;232:1-7 64. Zurrida S, Orecchia R, Galimberti V et al. Axillary radiotherapy instead of axillary

dissection: a randomized trial. Italian Oncological Senology Group. Ann Surg Oncol 2002;9:156-160.

65. Veronesi U, Paganelli G, Viale G et al Sentinel-Lymph-Node Biopsy as a Staging Procedure in Breast Cancer: Update of a Randomized Controlled Study. Lancet Oncol 2006; 7:983-90

66. Veronesi U, Galimberti V, Mariani L et al. Sentinel node biopsy in breast cancer:

early results in 953 patients with negative sentinel node biopsy and no axillary dissection. European Journal of Cancer 2005;41:231-237

67. Canavese G, Catturich A, Vecchio C et al. Sentinel Node Biopsy Compared With Complete Axillary Dissection for Staging Early Breast Cancer With Clinically Negative Lymph Nodes: Results of Randomized Trial. Ann Oncol 2009; 20:1001- 1007.

68. Naik AM, Fey J, Gemignani M et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: a follow-up study of 4008 procedures. Ann Surg 2004;240:462-8

69. Ashikaga T, Krag DN, Land SR et al. Morbidity results from the NSABP B-32 trial comparing sentinel lymph node dissection versus axillary dissection. J Surg Oncol 2010;102:111-118

70. Julian TB, Krag D, Brown A et al. Preliminary technical results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection to conventional axillary dissection in clinically node-negative breast cancer patients.

Breast Cancer Res Treat 2004; (suppl.11, abstr 14).

71. Julian TB, Anderson S, Brown A et al. Continued technical results of NSABP B-32:

does a positive sentinel node biopsy require an axillary dissection? Breast Cancer Res Treat 2005 (suppl.1, abstr 20).

72. Krag DN, Anderson SJ, Julian TB et al. Sentinel lymph node resection compared with conventional axillary lymph node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomized fase 3 trial. Lancet Oncol 2010;11:927-933

73. Julian TB, Anderson SJ, Krag DN et al. 10-yr follow-up results of NSABP B-32, a randomized phase III clinical trial to compare sentinel node resection (SNR) to conventional axillary dissection (AD) in clinically node negative breast cancer patients. J Clin Oncol 2013;31:abstr 1000

74. Gil PG. Sentinel Lymph node biopsy versus axillary cleareance in operable breast cancer: the RACS SNAC trial, a multicentre randomized trial Of the Royal Australian College of Surgeons (RACS) Section of Breast Surgery, in collaboration with the National Health and Medical Research Council Clinical trials centere. Ann Surg Oncol 2004;11:216S-221S

75. Veronesi U, Galimberti V, Paganelli G et al. Axillary metastases in breast cancer

patients with negative sntinel nodes:a follow up of 3548 cases. EJC 2009;45:1381-

1388

76. Al-Hajj M, Wicha MS, Benito-Hernandez A et al. Prospective identification of tumorigenic breast cancer cells.Proc Natl Acad Sci USA 2003;100:3983-88

77. Galimberti V, Manika A, Maisonneuve P et al. Long-term follow up of 5262 breast cancer patients with negative sentinel node and no axillary dissection confirms low rate of axillary disease. EJSO 2014;40:1203-1208

78. de Boniface J, Frisell J, Bergkvist L, Andersson Y. Ten-Year Report on Axillary Recurrence After Negative Sentile Node Biopsy for Breast Cancer from the Swedish Multicentre Cohort Study. 2016

79. Reimer T, Hartmann S, Stachs A et al. Local treatment of the axilla in early breast cancer:concepts from the National Surgical Adjuvant Breast and Bowel Project B- 04 to the planned Intergroup Sentinel Mamma Trial. Breast Care 2014;9:87-95 80. Zurrida S, Mazzarol G, Galimberti V et al. The problem of accuracy of

intraoperative examination of axillary sentinel nodes in breast cancer. Annals of Surgical Oncology 2001; 8(19):817-820

81. Viale G, Maiorano E, Pruneri G et al. Predicting the risk for additional axillary metastases in patients with breast carcinoma and positive sentinel lymph node biopsy. Ann Surg 2005;241:319-325

82. Naik AM, Fey J, Gemignani M et al. The risk of axillary relapse after sentinel lymph node biopsy for breast cancer is comparable with that of axillary lymph node dissection: A follow-up study of 4008 procedures. Ann Surg 2004; 240:462-471 83. Montgomery LL, Thorne AC, Van Zee KJ et al. Isosulfan blue dye reactions during

sentinel lynph node mapping for breast cancer. Anesth Analg 2002; 95:385-388.

84. Temple LK, Baron R, Cody HS 3

et al. Sensory morbidity after sentinel Lymph node biopsy and axillary dissection: A prospective study of 233 women. Ann Surg Oncol 2002; 28:705-710

85. Erickson VS, Pearson ML, Ganz PA et al. Arm edema in breast cancer patientsJ Natl Cancer Inst 2001; 93:96-111

86. Sener SF, Winchester DJ, Martz CH et al. Lymphedema after sentinel lymphadenectomy for breast carcinoma. Cancer 2001; 93:96-111

87. Moskovitz AH, Anderson BO, Yeung RS et al. Axillary web syndrome after axillary dissection. Am J Surg 2001; 181:434-439

88. Stearns V, Ewing CA, Slack R et al. Sentinel lymphadenectomy after neoadjuvant chemotherapy for breast cancer may reliably represent the axilla except for inflammatory breast cancer. Ann Surg Oncol 2002; 9:235-242

89. Espinoza-Bravo M, Navarrro-Cecilia J, Ramos Boyero M et al Intraoperative Assessment of Sentinel Lymph Node by One-Step Nucleic Acid Amplification In Breast Cancer Patients After Neoadjuvant Treatment Reduces the Need For A Second Surgery For Axillary Lymph Node Dissection. The Breast 2017; 31:40-45 90. Tamaki Y. One-step nucleic acid amplification (OSNA): where do we go with it?

91. Apple SK. Sentinel Lymph Node in Breast Cancer: Review Article from a Pathologist's Point of View. Journal of Pathology and Translational Medicine 2016;

50:83-95

92. Giuliano AE, Hunt KK, Ballman KV et al. Axillary Dissection vs No Axillary Dissection in Women With Invasive Breast Cancer and Sentinel Node Metastasis. A Randomized Clinical Trial. JAMA 2011; 305(6):569-575

93. Galimberti V, Cole BF, Zurrida S et al. Axillary dissection versus no axillary dissection in patients with sentinel node micrometastases (IBCSG 23-01): a phase 3 randomized controlled trial. Lancet Oncol 2013;14:297-305

94. Donker M, van Thienoven G, Straver ME et al. Radiotherapy or surgery of the

axilla after a positive sentinel node in breast cancer (EORTC 10981-22023

AMAROS): a randomized, multicentre, open label, phase 3 non inferiority trial.

Lancet Oncol 2014;15:1303-1310

95. Benerjee SM, Michalopoulos NV, Willians NR et al. Detailed evaluation of one step nucleic acid (OSNA) molecular assay for intra-operative diagnisis of sentinel lymphnode metastasis and prediction of non sentinel nodal involvement:

experience froma a London teaching Hospital. Breast 2014; 23:378-384

96. Deambrogio C, Castellano I, Paganott A et al. A new clinical cut-off of cytokeratin 19 mRNA copy number in sentinel lymph node better identifies patients eligible for axillary lymoh node dissection in breast cancer. J Clin Pathol 2014;67:702-706 97. Peg V, Espinosa-Bravo M, Vieites B et al. Intraoperative molecular analysis of total

tumor load in sentinel lymph node:a new predictor of axillary status in early breast cancer patients. Breast Cancer Res Treat 2013;139(87):87-93

98. Takamoto K, Shimazu K,Naomi Y et al. One-step nucleic acid amplification assay for detection of axillary lymph node metastases in breast cancer patients treated with neoadjuvant chemotherapy. Ann Surg Oncol 2016;23:78-86

99. Vietes B, Lopez-Garcia MA, Castilla C et al. CK19 expression in breast tumors and lymph node metastasis after neoadjuvant chemotherapy. Histopathology 2015;9(2):239-249

100.Sobin NH, Wittekind CH. TNM Classificazion of malignant tumours. 6

ed. New York:Wiley-Liss;2002

101.Viale G, Maiorano E, Mazzarol G et al. Histologic detection and clinical implications of micrometastases in axillary sentinel lymph nodes for patients with breast carcinoma. Cancer 2001; 92:1378-84

102.Fourquet A, Compana F, Safrani B et al. Prognostic factors of breast recurrence in the conservative management of early breast cancer:a 25-year follow-up. Int J Radiat Oncol Biol Phys 1989;17:719-725

103.Aberizk W, Silver B, Henderson IC et al. The use of radiotherapy for treatment of isolated locoregional recurrence of breast carcinoma after mastectomy. Cancer 1986;58:1214-1218

104.Morrow M, Rademaker AW, Bethke KP et al. Learning sentinel node biopsy:

results of a prospective randomized trial of two techniques. Surgery 1999; 126:714- 720

105.Chu KU, Turner RR, Hansen NM et al. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? Ann Surg 1999;229:536-41

106.Turner RR, Chu KU, Qi K et al. Pathologic features associated with nonsentinel lymph node metastases in patients with metastatic breast carcinoma in a sentinel lymph node. Cancer 2000;89:574-81

107.McCready DR, Yong WS, Ng AK et al. Influence of the new AJCC breast cancer staging system on sentinel lymph node positivity and false-negative rates. J Natl Cancer Inst 2004; 96:873-875

108.Wong SL, Edwards MJ, Chao C et al. Predicting the status of the nonsentinel axillary nodes: a multicenter study. Arch Surg 2001; 136:563-568

109.Marshall K, Redfern A, Cady B. Local recurrence of carcinoma of the breast. Surg Gynecol Obstet 1974;139:404-408

110.Weiser MR, Montgomery LL, Tan LK et al. Lymphovascular invasion enhances the prediction of non-sentinel node metastases in breast cancer patients with positive sentinel nodes. Ann Surg Oncol 2001;8:145-14

111. Tallet A, Lambaudie E, Cohen M, Minsat M, Bannier M, Resbeut M,

Houvenaeghel G. Locoregional Treatment of Early Breast Cancer With Isolated

Tumour Cells or Micrometastases on Sentinel Lymph Node Biopsy. World J Clin Oncol 2016; 7(2):243-252

112.Filtenborg Tvedskov T, Jensen MB, Ejlertsen B et al. Prognostic significance of axillary dissection in breast cancer patients with micrometastase or isolated tumor cells in sentinel nodes: a nationwide study. Breast Cancer Res Treat 2015

113.van Rijk MC, Peterse JL, Nieweng OE et al. Additional axillary metastases and stage migration in breast cancer patients with micrometastases or submicrometastases in sentinel lymph nodes. Cancer 2006;107:467-471

114.Rivers AK, Griffith KA, Hunt KK et al. Clinicopathologic features associated with having four or more metastatic axillary nodes in breast cancer patients with a positive sentinel lymph node. Ann Surg Oncol 2006;13:36-44

115.Zhou W, He Z, Xue J et al. Molecular subtype classification is a determnant of non-sentinel lymph node metastasis in breast cancer patients with positive sentinel lymph nodes. PloS One 2012;7:e35881

116.Houvenaeghel G, Nos C, Mignotte H et al. Micrometastases in sentinel lymph node in amulticentric study:predictive factors of non sentinel lymoh node involvement- Groupe des Chirurgiens de la Federation des Centres de Lutte Contre le Cancer. J Clin Oncol 2006;24:1814'1822

117.de Boer M, van Deurzen CH, van Dijck JA et al. Micrometastases and isolated tumour cells :relevant and robust or rubbish) (MIRROR): preliminary results of the MIRROR study from the Dutch breast cancer trialists groop (BOOG). Cancer Res 2009;69 (Suppl 2):70s abstr 23

118.Pepels MJ, de Boer M, Bult P et al. Regional recurrence in breast cancer patients with sentinel node micrometastases and isolated tumor cells. Ann Surg 2012;

255:116-121

119.Park J, Fey JV, Naik AM et al. A declining rate of completion axillary dissection in sentinel lymph node-positive breast cancer patients is associated with the use of a multivariate nomogram. Am Surg 2007;245:462-468

120.Fisher B, Brown A, Mamounas E et al. Effect of preoperative chemotherapy on locoregional disease in women with operable brest cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997;15:2483-2493 121.Gadd M, Harris J, Taghian A et al. Prospective study of axillary radiation without axillary dissection for breast cancer patients with a positive sentinel node.

Presented at San Antonio Breast Cancer Symposium, San Antonio, TX, Dec 2005;8-11

122.Colleoni M, Rotmensz N, Perruzzotti G et al. Size of breast cancer metastases in axillary lymph nodes:clinical relevance of minimal lymph node involvement. J Clin Oncol 2005;23:1379-1389

123.Montagna E, Viale G, Rotmensz N et al. Minimal axillary lymph node involvement in breast cancer has different prognostic implications according to the staging procedure. Breasr Cancer Res Treat 2009;118:385-394

124.Weaver DL, Ashikaga T, Krag DN et al. Effect of occult metastases on survival in node negative breast cancer. N Engl J Med 2011;364:412-421

125.Chen SL, Hoehne FM. The prognostic significance of micrometastases in breast cancer: a SEER population-based analysis. Ann Sur Oncol 2007;14(12):3378-3384 126.Cox CE, Kiluk JV, Riker AI et al.Significance of sentinel lymph node

micrometastases in human breast cancer. J Am Coll Surg 2008;206:261-268

127.van der Heiden-van der Loo M, Schaapveld M et al. Outcomes of a population

based series of early breast cancer patients with micrometastases and isolated tumor

cells in axillary lymph nodes. Ann Oncol 2013;24:2794-2801

128.International (Ludwig) Breast Cancer Study Group. Prognostic importance of occult axillary lymph node micrometastases from breast cancer. Lancet 1990;335:1565-1568

129.Truong PT, Vinh-Hung V, Cserni G et al. The number of positive nodes and the ratio of positive to excised nodes are significant predictors of survival in women with micrometastatic node-positive breast cancer. Eur J Cancer 2008;44(12):1670- 1677

130.Gobardhan PD, Elias SG, Madsen E et al. Prognostic value of micrometastases in sentinel lymph nodes of patients with breast carcinoma: a cohort study. Ann Oncol 2009;20(1):41-48

131.Hansen MN, Grube BJ, Te W et al. Clinical significance of axillary micrometastases in breast cancer:how small is too small?Proc Am Soc Clin Oncol 2001;20:24 abstr 91

132.Bilimoria KY, Bentrem DJ, Hansen NM, Bethke KP, Rademaker AW, Ko CY, Winchester DP, Winchester DJ. Comparison of Sentinel Lymph Node Biopsy Alone and Completion Axillary Lymph Node Dissection for Node-Positive Breast Cancer.

J Clin Oncol 2009; 27:2946-2953

133.Yi M, Giordano SH, Meric-Bernstam F et al. Trends in and outcomes from sentinel lymph node biopsy (SLNB) alone vs SLNB with axillary lymph node dissection for node positive breast cancer patients:experience from the SEER database. Ann Surg Oncol 2010;17(Suppl 3):343-51

134.Co M, Kwong A. Macrometastasis, micrometastasis and Isolated tumor cells in sentinel lymph nodes of early breast cancers: a 10-year histopathological and survival analysis of 537 Asian patients. World J Surg

135.Galimberti V, Botteri E, Chifu C et al. Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer? Breast Cancer Res Treat 2012;131:819-825

136.Houvenaeghel G, Boher JM, Reyal F et al. Impact of completion axillary lymph node dissection in patients with breast cancer and isolated tumor cells or micrometastases in sentinel nodes. European Journal of Cancer 2016;67:106-118 137.de Mascarel I, Bonichon F, Coindre JM et al. Prognostic significance of breast

cancer axillary lymph node micrometastases assessed by two special techniques:

Reevaluation with longer follow-up. Br J Cancer 1992; 66:523-527

138.Nasser IA, Lee AK, Bosari S et al. Occult axillary lymph node metastases in "node negative" breast carcinoma. Hum Pathol 1993; 24:950-957

139.Pickren J. Significance of occult metastases: A study of breast cancer. Cancer 1961; 14:1266-1271

140.Rosen PP, Saigo PE, Braun DW Jr et al. Occult axillary lymph node metastases from breast cancers with intramammary lymphatic tumour emboli. Am J Surg Pathol 1982; 6:639-641

141.Fisher ER, Swamidoss S, Lee CH et al. Detection and significance of occult axillary node metastases in patients with invasive breast cancer. Cancer 1978;

42:2025-2031

142.Trojani M, de Mascarel I, Bonichon F et al. Micrometastases to axillary lymph nodes from carcinoma of breast: Detection by immunohistochemistry and prognostic significance. Br J Cancer 1987; 55:303-306

143.Hainsworth PJ, Tjandra JJ, Stillwell RG et al. Detection and significance of occult metastases in node negative breast cancer. Br J Surg 1993; 80:459-463

144.McGuckin MA, Cummings MC, Walsh MD et al. Occult axillary node metastases

in breast cancer: Their detection and prognostic significance. Br J Cancer 1996;

73:88-95

145.Cote RJ, Peterson HF, Chaiwun B et al. Role of immonohistochemical detection of lymphnode metastases in management of breast cancer. International Breast Cancer Study Group. Lancet 1999; 354:896-900

146.Klauber-De More N, Tan LK, Liberman L et al. Sentinel lymph node biopsy: is it indicated in patients with high-risk ducatl carcinoma in situ and ductal carcinoma in situ with microinvasion?Ann Surg Oncol 2000;7:636-642

147.Lyman GH, Temin S, Edge SB al. Sentinel lymph node biopsy for patients with early syage breast cancer: American Society of Clinical Oncology clinical practice Guideline. J Clin Oncol 2014; 32:1365-83

148.Zavagno G, Carcoforo P, Marconato R et al. Role of axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. BMC Cancer 2005;5:28

149.Kelly TA, Kim JA, Patrik R et al. Axillary lymph node metastases in patients with a final diagnosis of ductal carcinoma in situ. Am J Surg 2003;186:360-370

150.Silverstein MJ, Skinner KA, Lomis TJ. Predicting axillary nodal positivity in 2282 patients with breast carcinoma. World J Surg 2001;25:767-772

151.Penda S, Dauway E, Giuliano R et al. Sentinel node biopsy in ductal carcinoma in situ patients. Ann Surg Oncol 2000;7:15-20

152.Cox CE, Nguyen K, Gray RJ et al. Importance of lymphatic mapping in ductal carcinoma in situ (DCIS):why map DCIS? Am Surg 2001;67:513-519

153.Intra M, Veronesi P, Mazzarol G et al. Axillary sentinel lymph node biopsy in patients with pure ductal carcinoma in situ of the breast. Arch Surg 2003;138:309- 313

154.Farkas EA, Stolier AJ, Teng SC et al. An argument against routine sentinel node mapping for DCIS. Am Surg 2004;70:13-18

155.King TA, Farr GH jr, Cederbom GJ et al. A mass on breast imaging predicts coexising invasive carcinoma in patients with a core biopsy diagnosis of ductal carcinoma in situ. Am Surg 2001;67:907-912

156.Zunzunegui RG, Chumg MA, Oruwari J et al. Casting-type calcifications with invasion and high grade ductal carcinoma in situ:a more aggressive disease? Arch Surg 2003;138:537-540

157.Intra M, Trifirò G, Viale G et al. Second biopsy of axillary sentinel lymph node for reappearing breast cancer after previous sentinel lymph node biopsy. Annals of Surgical Oncology 2005;12(11):895-899

158.Tausch C, konstantiniuk P, Kugler F et al. Sentinel Lymph node biopsy after preoperative chemotherapy for breast cancer: findings from the Australian Sentinel Node study group. Ann Surg Oncol 2007

159.Intra M, Viale G, Grana CM et al. Second Axillary sentinel lymph node biopsy for breast tumor recurrence:experience of the European Institute of Oncology. Ann Surg Oncol 2014

160.Taback B, Nguyen P, HansenN et al. Sentinel Lymph node biopsy for local recirrence of breast cancer after breast-conserving therapy. Ann Surg Oncol 2006;13:1099-1104

161.Port ER, Garcia-Etienne CA, Park J et al. Reoperative sentinel lymph node biopsy:a new frontier in the management of ipsilateral breast tumour recurrence.

Ann Surg Oncol 2007;14:2209-2214

162.Maaskant-Braat AJ, Voogd AC, Roumen RM et al. Repeat sentinel node biopsy in

patients with locally recurrent breast cancer: a systematic review and meta-analysis

of the literature. Breast Cancer Res Treat 2013;138:13-20

163.Galimberti V, Chifu C, Rodriguez Perez S et al. Positive axillary sentinel lymph node: is axillary dissection always necessary? The Breast 2011;20:96-98

164.Fant JS, Grant MD, Knox SM et al. Preliminary outcome analysis in patients with breast cancer and a positive sentinel lymph node who declined axillary dissection.

Ann Surg Oncol 2003; 10:126-130

165.Grube BJ, Giuliano A. Observation of the breast cancer patient with a tumour- positive sentinel node: implications of the ACOSOG Z0011 Trial.Semin Surg Oncol 2001; 20:230-237

166.Guenther JM, Hansen NM, DiFronzo LA et al. Axillary dissection is not required for all patients with breast cancer and positive sentinel nodes. Arch Surg 2003;

138:52-56

167.Veronesi U, Orecchia R, Zurrida S et al. Avoiding axillary dissection in breast cancer surgery:a randomized trial to assess the role of axillary radiotherapy.Ann Oncol 2005;16:259-62

168.Van Zee KJ, Manasseh DM, Bevilacqua JL et al. A nomogram for predicting the likelihood of additional nodal metastases in breast cancer patients with a positive sentinel node biopsy. Ann Surg Oncol 2003; 10:1140-1151

169.Hwang RF, Gonzales-Angulo AM, Yi M, Buchholz TA et al. Low locoregional Failure Rates in Selected Breast Cancer Patients With Tumour-positive Sentinel Lymph Nodes Who Do Not Undergo Completion Axillary Dissection. Cancer 2007;

110:723-730

170.Lucci A, Mackie McCall L, Beitsch PD, Whitworth PW et al. Surgical complications Associated With Sentinel Lymph Node Dissection (SLND) Plus Axillary Lymph Node Dissection Comapred With SLND Alone in the American College of Surgeons Oncology Group Trial Z0011. J Clin Oncol 2007; 25:3657- 3663

171.Linehan D, Hill AD, Akhurst T et al. Intradermal radiocollioid and intraparenchymal blue dye injection optimize sentinel node identification in breast cancer patients. Ann Surg Oncol 1999; 6:450-454

172.Hill AD, Tran KN, Akhurst T et al. Lessons learned from 500 cases of lymphatic mapping for breast cancer. Ann Surg 1999;229:528-535

173.Reynolds C, Mick R, Donohue JH et al. Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer? J Clin Oncol 1999;17:1720-6

174.Fidler IJ. The pathogenesis of cancer metastases:the seed and soil hypothesis revisited. Nat Rev Cancer 2003;3(6):453-458

175.Singletary S. Systemic treatment after sentinel lymph node biopsy in breast cancer:who, what and why? J Am Coll Surg 2001;192:220-230

176.Mansour E, Gray R, Shatila AH et al. Efficacy of adjuvant chemotherapy in high- risk node-negative breast cancer. N Engl J Med 1989;320:485-490

177.McGuire W. Adjuvant therapy of node-negative breast cancer. N Engl J Med 1989;320:525-527

178.Early breast cancer trialists' Collaborative group:systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy. Lancet 1992;339(8784):1-15;

(8785):71-85

179.Fiscer B, Dignam J, Wolmark N et al. Ramoxifen and chemotherapy for lymph node negative, estrogen receptor positive breast cancer. J Clin Oncol 1997;89:1673- 1682

180.Moffat F, Seza AG, Sittler SY et al. Unfiltered sulfur colloid and sentinel node

biopsy for breast cancer:technical and kinetic considerations. Ann Surg Oncol

1999; 6:746-755

181.Buzdar A, Singletary SE, Theriault RL et al. Prospective evaluation of paclitaxel versus combination chemotherapy with fluorouracil, doxorubicin and cyclophosphamide as neoadjuvant therapy in patients with operable breast cancer. J Clin Oncol 1999;17:3412-3417

182.Danforth D, Zujewski J, O'Shaughnessy J et al. Selection of local therapy aftyer neoadjuvant chemotherapy in patients with stage IIIA,B breast cancer. Ann Surg Oncol 1998;5:150-158

183.Veronesi U, Viale G, Paganelli G et al. Sentilel Lymph node biopsy in breast cancer: 10-year results of a randomized controlled study. Ann Surg 2010;251:595- 600

184.Wong J, Recht A, Beard CJ et al. Treatment outcome after tangential radiation therapy without axillary dissection in patients with early-stage breast cancer and clinically negative nodes. Int J Radiat Oncol Biol Phys 1997;39:915-920

185.Pejavar S, Wilson LD, Haffty BG. Regional nodal recurrence in breast cancer patients treated with conservative surgery and radiation therapy (BCS+RT). Int J Radiat Oncol Biol Phys 2006;66:1320-1327

186.Jeruss JS, Sener SF, Brinkmann EM et al. Axillary recurrence after sentinel node biopsy. Ann Surg Oncol 2005;12:34-40

187.Braun S, Pantel K, Muller P et al. Cytokeratin-positive cells in the bone marrow and survival of patients with ge I,II or III breast cancer. N Engl J Med 2000;342:525-533

188.Fisher B, Jeong JH, Anderson S, Bryant J, Fisher E, Wolmark N. Twenty-Five- Year Follow-Up of a Randomized Trial comparing Radical Mastectomy, Total Mastectomy, and Total Mastectomy followed by Irradiation. N Engl J Med 2002;

347:567-75

189.Fisher B, Montague E, Redmond C et al. Comparison of radical mastectomy with alternative treatments for primary breast cancer: a first report of results from a prospective randomized clinical trial. Cancer 1977; 39:2827-39

190.Fisher B, Gebhardt MC. The evolution of breast cancer surgery: past, present and future. Semin Oncol 1978; 5:385-94

191.Fisher B. A biological perspective of breast cancer: contributions of the Nationa SurgicalAdjuvant Breast and Bowel Project clinicl trials. CA Cancer J Clin 1991;

41:97-111

192.McArdle C, Crawford D, Dykes EH et al. Adjuvant radiotherapy and chemotherapy in breast cancer. Br J Surg 1986;73:264-266

193.Fisher ER, Palekar A, Rockette H et al. Pathologic findings from the National Surgical Adjuvant Breast Project (protocol no.4). Cancer 1978;42:2032-8

194.Early Breast Cancer Trialists Collaborative Group. Favourable and unfavourable effects on long term survival of radiotherapy for early breast cancer: an overview of the randomized trials. Lancet 2000; 355:1757-70

195.Early Breast Cancer Trialists' Collaborative Group:effects of radiotherapy and surgery in early breast cancer. N Engl J Med 1995;333:1444-1455

196.Olson JA, McCall LM, Beitsch P et al. Impact of immediate vs delayed axillary node dissection on surgical outcomes in breast cancer patients with positive sentinel nodes:results from American College of Surgeons Oncology Group Trial Z0010 and Z0011. J Clin Oncol 2008;26:3530-3535

197.Rietnam JS, Geertzen JH, Hoekstra HJ et al. Long term treatment related upper

limb morbidity and quality of life after sentinel lymph node biopsy for stage I or II

breast cancer. Eur J Surg Oncol 2006;32:148-152

198.Meric F, Buchholtz TA, Mirza NQ et al. Long term complications associated with breast conservation surgery and radiotherapy. Ann Surg Oncol 2002;9:543-549 199.Schulze T, Mucke J, Markwardt J et al. Long term morbidity of patients with early

breast cancer after sentinel lymph node biopsy compared to axillary lymph node dissection. J Surg Oncol 2006;93:109-119

200.Wilke LG, McCall LM, Posther KE et al. Surgical complications associated with sentinel lymph node biopsy: results from a prospective international cooperative group trial. Ann Surg Oncol 2006;13:491-500

201.Robertson JFR, Herrod PJJ, Matthew J, et al Treatment of the Axilla in Patients With Primary Breast Cancer and Low Burden Axillary Disease: Limitations of the Evidence from Randomized Controlled Trials. Critical Reviews in Oncology/Hematology 2017; 110:74-80

202.Chung A, Gangi A, Mirocha J et al. Applicability of the ACOSOG Z0011 criteria in women with high-risk node-positive breast cancer undergoing breast conserving surgery. Ann Surg Oncol 2015;22:1128-1132

203.Giuliano A, Morrow M, Duggal S et al. Sholud ACOSOG Z0011 change paractice with respect to axillary lymph node dissection for a positive sentinel lymph node biopsy in breast cancer? Clin Exp Metastasis 2012;29:687-692

204.Wiechmann L, Sampson M, Stempel M et al. Presenting features of brest cancer differ by molecular subtype. Am Surg Oncol 2009;16:2705-2710

205.Anderson WF, Chen BE, Jatoi I et al. Effects of estrogen receptor expression and histopathology on annual Hhazard rates of death from breat cancer. Breast Cancer Res Treat 2006; 100:121-126

206.Colleoni M, Sun Z, Price KN et al. Annual Hazard Rates of Recurrence for Breast Cancer during 24 years of follow-up: Results from the International Breast Cancer Study Group Trials I To V; J Clin Oncol 2016; 34:927-935

207.Giuliano AE, Ballman K, McCall L et al. Locoregional recurrence after sentinel lymph node dissectION with or without axillary dissection in patients with sentinel lymph node metastases. Long Term follow-up from the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 randomized trial. Ann Surg 2016; 264:413-420

208.Whelan TJ, Olivotto IA, Parulekar WR et al. MA.20 Study Invesrigators..Regional nodal irradiation (RNI) in early stage breast cancer. N Engl J Med 2015; 373:307- 316

209.Savolt A, Peley G, Polgar C, et al Eight-year Follow-up Result of the OTOASOR Trial: The Optimal Treatment of The Axilla-Surgery Or Radiotherapy After Positive Sentinel Lymph Node Biopsy in Early-Stage Breast Cancer. A Randomized, Single- Center, Phase III, Non-Inferiority Trial. EJSO 2017

210.Gentilini O, Veronesi U. Abandoning sentinel lymph node biopsy in eearly breast cancer? A new trial in progress at the European Institute of Oncology of Milan (SOUND:Sentinel node vs Observation after axillary UltrasouND). The Breast 2012;221:678-681

211.Gentilini O, Botteri E, Daddaa P et al. Physica function of the upper limb after breast cancer surgery. Results from the DOUND (Sentinel node vs Observation after axillary Ultra-souND) trial. EJSO 2016;1-5

212.King TA, Morrow M. Surgical issues in patients with breast cancer receiving neoadjuvant chemotherapy. Nat Rev Clin Oncol advance online publication 7 April 2015; doi:10.1038/nrclinonc.2015.63

213.Staver ME, Rutgers EJ, Russel NS et al. Towards rational axillary treatment in

relation to neoadjuvant therapy in breast cancer. Eur J Cancer 2009;45:2284-92

214.Boughey JC, Suman VJ, Mittendorf EA et al. Sentinel lymph node surgery after Neoadjuvant chemotherapy in patients with node-positive breast cancer: The American College of Surgeons Oncology Group (ACOSOG) Z1071 Clinical Trial.

JAMA 2013;310 (14):1455-1461

215.Kim JY, Kim MK, Lee JE, Jung Y, Bae SY, Lee SK, Kil WH, Kim SW, Kim KS, Nam SJ, Han S. Sentinel Lymph Node Biopsy Alone after Neoadjuvant Chemotherapy in Patients with Initial Cytology-Proven Axillary Node Metastasis. J Breast Cancer 2015; 18(1): 22-28

216.Vriens BEPJ, Keymeulen KBMI, Kroep JR, Charehbili A, Peer PG, de Boer M, Aarts MJB, Heuts EM, Tjan-Heijenen VGC, The Dutch Breast Cancer Research Group (BOOG). Axillary Staging in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy in Two Dutch Phase III Studies. Oncotarget 2017;

217.Boughey JC, Ballman KV, Le Petross HT et al. Identification and resection of the clipped node decreses the false negative rate of sentinel lymph node surgery in patients presentingwith with node positive breast cancer (T0-T4,N1-2) who receive neoadjuvant chemotherapy: results from the ACOSOG Z1071 trial (Alliance). Ann Surg 2016;263(4):802-807

218.Sabel MS, Schott AF, Kleer CG et al. Sentinel node biopsy prior to neoadjuvant chemotherapy. Am J Surg 2003; 186:102-105

219.Jones JL, Zabicki K, Christian RL et al. A comparison of sentinel node biopsy before and after neoadjuvant chemotherapy: timing is important. Am J Surg 2005;190:517-20

220.Schrenk P, Tausch C, Wolf S et al. Sentinel node mapping performed before preoperative chemotherapy may avoid axillary dissection in breast cancer patients with negative or micrometastatic sentinel nodes. The American Journal of Surgery 2008;196:176-193

221.Garcia-Tejedor A, Falo C, Quetglas C, et al Accuracy and Prognosis of Sentinel Lymph Node Biopsy before Neoadjuvant Therapy in Breast Cancer. A prospective Study. International Journal of Surgery 2017; 39:141-147

222.Chung A, Giuliano A. Axillary staging in the neoadjuvant setting. Ann Surg Oncol 2010;17:2401-10

223.Rouzier R, Perou CM, Symmans WF et al. Breast cancer molecular subtypes respond differently to preoperative chemotherapy. Clin Cancer Res 2005;11:5678- 85

224.Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant vs Adjuvant systemic treatment in breast cancer:a meta-analysis. J Natl Cancer Inst 2005; 97:188-194

225.Morrow M. Patterns of care with a positive sentinel node:echoes of an opportunity missed. Ann Surg Oncol 2009;16(9):2429-30

226.Mamtani A, Barrio AV, King TA, et al How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective study. Ann Surg Oncol 2016 227.Kelly AM, Dwamena B, Cronin P et al. Breast cancer sentinel node identification and classification after neoadjuvant chemotherapy: sistematic review and metaanalysis. Acad Radiol 2009; 16:551-63

228.Hunt KK, Yi M, Mitterndorf EA et al. Sentinel Lymph node surgery after neoadjuvant chemotherapy is accurate and reduces the need for axillary dissection in breast cancer patients. Ann Surg 2009;250:558-66

229.Alvarado R, Yi M, Le-Petross H et al. The role for sentinel lymph node dissection

after neoadjuvant chemotherapy in patients who present with node-positive breast

cancer. Ann Surg Oncol 2012;19:3177-84

230.Tabahashi M, Jinno H, Hayashida T et al. Correlation between clinical nodal status and sentinel lymph node biopsy false negative rate after neoadjuvant chemotherapy.

World J Surg 2012;36:2847-52

231.Mocellin S, Goldin E, Marchet A et al. Sentinel node biopsy performance after neoadjuvant chemotherapy in locally advanced breast cancer: a systematic review and meta-analysis. Int J Cancer 2016;138:472-80

232. Mamounas EP, Brown A, Anderson S et al. Sentinel node biopsy aftern neoadjuvant chemotherapy in breast cancer:results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2005;23:2694-702 233.Newman EA, Sabel MS, Nees AV et al. Sentinel lymph node biopsy performed

after neoadjuvant chemotherapy is accurate in patients with documented node- positive breast cancer at presentation. Ann Surg Oncol 2007;14:2946-52

234.Classe JM, Bordes V, Campion L et al. Sentinel lymph node biopsy after neoadjuvant chemotherapy for advanced breast cancer:results og ganglion sentinelle et chemiotherapie neoadjuvante, a French prospective multicentric study.

J Clin Oncol 2009;27:726-32

235.Canavese G, Dozin B, Vecchio C et al. Accuracy of sentinel lymph node biopsy after neo-adjuvant chemotherapy in patients with locally advanced breast cancer and clinically positive axillary nodes. EJSO 2011;37:688-694

236.Kuehn T, Bauerfeind I, Fehm T et al. Sentinel lymph-node biopsy in patients with breast cancer before and after neoadjuvant chemotherapy (SENTINA): a prospective, multicentre cohort study. Lancet Oncol 2013;14:609-18

237.Boileau JF, Pirier B, Basik M et al. Sentinel Node Biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study. J Clin Oncol 2015;33:258-264

238.Zetterlund L, Celegioglu F, Axelsson R, de Boniface J, Frisell J. Swedish Prospective Multicenter Trial on The Accuracy and Clinical Relevance of Sentinel Lymph Node Biopsy before Neoadjuvant Systemic Therapy in Breast Cancer.

Breast Cancer Res Trea 2017

239.Holmstrand Zetterlund L, Frisell J, Zouzos A, Axelsson R, Hatschek T, de Boniface J, Celebioglu F. Swedish Prospective Multicentre Trial Evaluating Sentinel Lymph Node Biopsy After Neoadjuvant Systemic Therapy in Clinically Node-Positive Breast Cancer. Breast Cancer Res Treat 2017;

240.Enokido K, Watanabe C, Nakamura S et al. Sentinel lymoh node biopsy after neoadjuvant chemotherapy in patients with an initial diagnosis of citology-proven lymph node positive breast cancer. Clinical Breat Cancer 2026.

241.Galimberti V, Ribeiro Fontana SF, Maisonneuve P et al. Sentinel node biopsy after neoadjuvant treatment in breast cancer: five-year follow-up of patients with clinically node-negative or node-positive disease before treatment, EJSO 2016;42:361-368

242.Park S, Lee JE, Paik H-J, Ryu JM, Bae SY, Lee SK, Kim SW, Nam SJ. Feasibility and Prognostic Effect of Sentinel Lymph Node Biopsy After Neoadjuvant Chemotherapy in Cytology-Proven, Node-Positive Breast Cancer. Clinical Breast Cancer 2016

243.Mauri D, Pavlidis N, Ioannidis JP. Neoadjuvant vs Adjuvant systemic treatment in breast cancer:a meta-analysis. J Natl Cancer Inst 2005; 97:188-194

244.Donker M, Straver ME, Wesseling J et al. Marking axillary lymph nodes with radioactive iodine seeds for axillary staging after neoadjuvant systemic treatment in breast cancer patients: the MARI procedure. Ann Surg 2015;261;378-82

245.Nathanson SD, Burke M, Slater R et al. Preoperative identification of the sentinel

lymph node in breast cancer. Ann Surg Oncol 2007;14(11):3102-10

246.Caudle AS, Yang WT, Krishnamurthy S et al. Improved axillary evaluation following neoadjuvant therapy for patients with node positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection. J Clin Oncol 2016;34:1072-1078

247.Schmidt-Hansen M, Bromham N, Hasler E et al. Axillary surgery in women with sentinel node-positive operable breast cancer: a systematic review with meta- analyses. Springerplus 2016;5:85

248.Network NCCN. NCCN Clinical Practice Guidelines in Oncology, Version 22016.

Invasive breast cancer.2016

249.Tinterri C, Canavese G, Bruzzi P et al. SINODAR ONE, an ongoing randomized clinical trial to assess the role of axillary surgery in breast cancer patients with one or two macrometastatic sentinel nodes. The Breast 2016;1-4

250.Reimer T, Hartmann S, Stachs A et al. Local treatment of the axilla in early breast cancer:concepts from the National Surgical Adjuvant Breast and Bowel Project B- 04 to the planned Intergroup Sentinel Mamma Trial. Breast Care 2014;9:87-95 251.Goyal A, Dodwell D. PONSOC: a randomized trial looking at axillary treatment in

women with one or two sentinel nodes with macrometastases. Clin Oncol

2015;27:692-5